Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

New Zealand firm Proacta gets $8.2mm in Series A; adds $4mm

Executive Summary

Cancer company Proacta Therapeutics Ltd. (a cooperative venture between the University of Auckland and Stanford University) brought in $8.2mm (NZD12.5mm) with a Series A venture round led by GBS Venture Partners. Also participating in the financing were Endeavour i-cap, Genentech, New Zealand Venture Investment Fund, No. 8 Ventures Management Ltd., and Roche's venture capital arm Roche Venture Fund.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies